BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10679300)

  • 1. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon.
    Mineo R; Fichera E; Liang SJ; Fujita-Yamaguchi Y
    Biochem Biophys Res Commun; 2000 Feb; 268(3):886-92. PubMed ID: 10679300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human insulin-like growth factor-II promoter P1 is not restricted to liver: evidence for expression of P1 in other tissues and for a homologous promoter in baboon liver.
    Jin IH; Sinha G; Yballe C; Vu TH; Hoffman AR
    Horm Metab Res; 1995 Oct; 27(10):447-9. PubMed ID: 8575722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
    Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Schwartz P; Yu H
    Gynecol Oncol; 2006 Dec; 103(3):990-5. PubMed ID: 16859738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues.
    Fichera E; Liang S; Xu Z; Guo N; Mineo R; Fujita-Yamaguchi Y
    Growth Horm IGF Res; 2000 Apr; 10(2):61-70. PubMed ID: 10931743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Insulin-like growth factor 2 imprinting status and promoter usage in the placenta of macrosomia].
    Yao JC; Hu YL; Wang ZQ; Dai YM; Ling JX; Ye XD
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):309-14. PubMed ID: 17673042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-II in primary human colorectal tumors: peptide level, activated promoters, parental imprinting and gene rearrangement.
    Winkler R; Delacroix L; Bensbaho K; Lambert S; Collette J; Hodzic D
    Horm Metab Res; 1999; 31(2-3):148-54. PubMed ID: 10226796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues.
    Jarrard DF; Bussemakers MJ; Bova GS; Isaacs WB
    Clin Cancer Res; 1995 Dec; 1(12):1471-8. PubMed ID: 9815946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors.
    Weng J; Ma W; Mitchell D; Zhang J; Liu M
    J Cell Biochem; 2005 Dec; 96(5):1034-48. PubMed ID: 16149059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.
    Tang SH; Yang DH; Huang W; Zhou HK; Lu XH; Ye G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4171-7. PubMed ID: 16857788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning, characterization and promoter analysis of the common carp IGF-II gene.
    Tse MC; Chan KM; Cheng CH
    Gene; 2008 Apr; 412(1-2):26-38. PubMed ID: 18304762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
    Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization.
    Gallagher EM; O'Shea DM; Fitzpatrick P; Harrison M; Gilmartin B; Watson JA; Clarke T; Leonard MO; McGoldrick A; Meehan M; Watson C; Furlong F; O'Kelly P; Fitzpatrick JM; Dervan PA; O'Grady A; Kay EW; McCann A
    Clin Cancer Res; 2008 Nov; 14(21):6829-38. PubMed ID: 18980977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter-specific insulin-like growth factor 2 gene imprinting in human fetal liver and hepatoblastoma.
    Yun K; Jinno Y; Sohda T; Niikawa N; Ikeda T
    J Pathol; 1998 May; 185(1):91-8. PubMed ID: 9713365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genomic imprinting of insulin-like growth factor II in prostate cancer and its clinical significance].
    Liu ZW; Zhou FJ; Luo YM; Qin ZK; Wang DJ; Luo JH; Han H; Li YH; Wang H
    Ai Zheng; 2006 Jun; 25(6):765-70. PubMed ID: 16764778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
    Nosho K; Yamamoto H; Taniguchi H; Adachi Y; Yoshida Y; Arimura Y; Endo T; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Dec; 10(23):7950-7. PubMed ID: 15585629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic organization and structure of the 5'-flanking region of the TEX101 gene: alternative promoter usage and splicing generate transcript variants with distinct 5'-untranslated region.
    Tsukamoto H; Takizawa T; Takamori K; Ogawa H; Araki Y
    Mol Reprod Dev; 2007 Feb; 74(2):154-62. PubMed ID: 16941676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter].
    Zhou HK; Yang DH; Tang SH; Huang W; Lu XH
    Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):106-10. PubMed ID: 16620715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel first exons in Ad4BP/SF-1 (NR5A1) gene and their tissue- and species-specific usage.
    Kimura R; Yoshii H; Nomura M; Kotomura N; Mukai T; Ishihara S; Ohba K; Yanase T; Gotoh O; Nawata H; Morohashi K
    Biochem Biophys Res Commun; 2000 Nov; 278(1):63-71. PubMed ID: 11071856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta.
    Zhou J; Gurates B; Yang S; Sebastian S; Bulun SE
    Cancer Res; 2001 Mar; 61(5):2328-34. PubMed ID: 11280806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative promoter usage and alternative splicing contribute to mRNA heterogeneity of mouse monocarboxylate transporter 2.
    Zhang SX; Searcy TR; Wu Y; Gozal D; Wang Y
    Physiol Genomics; 2007 Dec; 32(1):95-104. PubMed ID: 17911380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.